[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100160772":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":10,"locations":24,"responsibleParty":48,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":69,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Sildenafil ≥20mg three times daily",null,"Subjects receiving sildenafil ≥20mg three times daily for the treatment of PAH",[13],"Drug: sildenafil citrate",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","sildenafil citrate","Sildenafil citrate, 20mg oral tablets, taken at least three times daily",[9],[21],{"name":22,"affiliation":5,"role":23},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[25,37],{"facility":26,"status":10,"city":27,"state":10,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Medizinische Hochschule Hannover","Hanover","30625","Germany","DE",{"type":32,"coordinates":33},"Point",[34,35],9.73322,52.37052,{"lat":35,"lon":34},{"facility":38,"status":10,"city":39,"state":10,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":47,"contacts":10},"Mater Misericordiae Hospital","Dublin","7","Ireland","IE",{"type":32,"coordinates":44},[45,46],-6.24889,53.33306,{"lat":46,"lon":45},{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100160772","evaluate-the-clinical-effectiveness-safety-and-tolerability-of-sildenafil-used-in-doses-20mg-tid-for-the-treatment-of-pulmonary-arterial-hypertension-100160772",true,"NCT01365585","Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension","Inclusion Criteria:\n\n* Patients must be at least 18 years of age at study index;\n* Patients must have a diagnosis of PAH. PAH is conventionally defined as a mean pulmonary arterial pressure (PAP) of \\> 25 mmHg and a pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg and a pulmonary vascular resistance (PVR) ≥ 240 dynes\u002Fs\u002Fcm-5 at right heart catheterization;\n* Patients must have initiated sildenafil for the treatment of their PAH; at dose ≥ 20 mg tid within 5 years prior to study initiation\n\nExclusion Criteria:\n\n* Patient has known contraindications to sildenafil at study index;\n* Patient participated in an investigational study of sildenafil treatment for PAH during the period beginning 6 months prior to study index",false,"ALL","18 Years",{"count":60,"type":61},227,"ACTUAL","OBSERVATIONAL","The objective of this observational study is to gain clinical insight on the actual use of sildenafil citrate (Revatio™) for the treatment of pulmonary arterial hypertension (PAH). The primary objective is to assess effectiveness and safety of sildenafil at doses ≥20mg three times daily for the treatment of PAH.",[65],"Pulmonary Arterial Hypertension",[67,17,68],"Pulmonary arterial hypertension","Revatio","COMPLETED","2021-01-28",{"date":72,"type":61},"2021-02-01",{"date":74,"type":10},"2011-07",{"date":76,"type":61},"2011-10",{"name":78,"class":6},"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",2]